Prof Ciro Rinaldi
@tamaciro
Followers
1K
Following
843
Media
248
Statuses
1K
Group Deputy Chief Medical Officer, Director of Research & Innovation - Professor of haematology
Lincolshire UK
Joined March 2010
Great work Anya! From our lab. a great team work @DrMattSimmonds presented at @ESIDsociety @EHA_Hematology
0
0
4
Red Cells ........All Different types 😀 #hematology #medtwitter #hemepath #blooducation #meded credit : Barbara Bain - who else can it be 😃
1
33
95
Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia @BrJHaem
https://t.co/adn6gi8WnJ
onlinelibrary.wiley.com
Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard-dose cytarabine (‘7 + 3’) despite complete response (CR) rates...
1
21
78
2/#ASH25 Myeloproliferative syndromes and neoplasms: beyond JAK inhibitors Activin receptor targeting: Elritercep (KER-050, TAK-226) @tamaciro
https://t.co/7jW5ac78S2 zilurgisertib (INCB000928) @bose_prithviraj
https://t.co/5FiWicCvSp
1
1
3
HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to @JNJInnovMed and the huge worldwide team of investigators for
9
72
255
Daratumumab is now FDA and EU approved for treatment of high risk smoldering myeloma. It is recommended level 1 by NCCN. My thoughts: In the AQUILA randomized trial, daratumumab: -Prolonged time to active myeloma -Prolonged time to end organ damage -Delayed time to needing
6
31
112
Prof Ciro Rinaldi Invites to Join MPN session ASH2025 @tamaciro | @ASH_hematology
https://t.co/O4dJZWzuvr
#Health #Hematology #Hemostasis #HemostasisToday #Medicine #MPNSession #ASH #MedEd #MedX
0
2
7
@NEJM @ASH_hematology @thanosdimop EU approval was in July. I’m really glad to have FDA approval. This is just huge news for the field. And for patients. @NorthTxMSG @MyelomaTeacher
Finally. We have European regulatory approval for high risk smoldering myeloma! Await FDA decision. AQUILA trial. @NEJM Darzalex (Daratumumab)
2
4
14
NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from posttransplant gilteritinib. https://t.co/fCONZjmgb8
#clinicaltrialsandobservations #myeloidneoplasia
1
8
36
Mitochondrial biogenesis made "simple" Your cells don’t just rely on the mitochondria they’re born with. They can make new ones when energy demand increases. This process, called mitochondrial biogenesis, keeps your energy systems strong and resilient. 1️⃣ Why It Happens
10
155
540
One of my patient still in remission after 7 years in Agile !
Among patients with mutant IDH1 AML in complete remission with ivosidenib-azacitidine, 30% experienced deep molecular clearance on treatment. https://t.co/wJSIUHilKD
#clinicaltrialsandobservations
0
0
2
Among patients with mutant IDH1 AML in complete remission with ivosidenib-azacitidine, 30% experienced deep molecular clearance on treatment. https://t.co/wJSIUHilKD
#clinicaltrialsandobservations
1
13
35
Together with my mentor @lab_rezvani Katy Rezvani @MDAndersonNews, I am excited to share our new review in Cancer Cell: “Engineered natural killer cells for cancer therapy”. Deeply grateful for Katy’s mentorship and her visionary leadership. #CARNK #Immunotherapy #SolidTumors
Online Now: Engineered natural killer cells for cancer therapy
4
29
98
A clinical guide to TP53 mutations in myeloid neoplasms https://t.co/aNCsqyO3lm
#myeloidneoplasia
0
7
39
High JAK2V617F allele burden in low-risk PV: an additional recommendat... https://t.co/QI7FPsCK95 interesting paper and potential practice changer
0
2
15
2) We welcome new expert faculty member, Dr Claire Harrison @harrisoncn1, clinician, educator, & Prof of Haematology at the Guy’s & St. Thomas’ NHS Foundation Trust @GSTTnhs in London 🇬🇧, where she is also Prof of Myeloproliferative Neoplasms & Deputy Chief Medical Officer
1
2
4